# US 2022/0090096 A1 · Genetic construct

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0090096 A1
- Document ID: US20220090096A1
- Status: Published application
- Kind: A1
- Application number: 17/426,095
- Filed: 2020-01-28
- Published: 2022-03-24
- Earliest claimed: 2019-01-28
- Assignees: The University of Nottingham
- Applicants: The University of Nottingham
- Inventors: Nigel Minton; Ines Canadas Blasco; Daphne Groothuis; Maria Zygouropoulou
- Web page: https://patentgrep.com/patent/US20220090096A1

## CPC

- C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
- C12N 15/74: Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
- C07K 14/33: from Clostridium (G)
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12N 15/63: Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N 15/115: Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith {; Nucleic acids binding to non-nucleic acids, e.g. aptamers}
- C12N 2310/16: Aptamers
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2330/51: Specially adapted vectors
- C12N 2800/101: for bacteria
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

A genetic construct comprising a DNA polynucleotide sequence which encodes a riboswitch operably linked to a coding region, wherein the coding region encodes a target gene and the riboswitch modulates translation or transcription of the coding region. A vector or a host cell comprising the genetic construct of the invention. A method of controlling expression of a target gene in a cell using the genetic construct of the invention.

## Claims

### Claim 1

A genetic construct comprising a DNA polynucleotide sequence which encodes a riboswitch operably linked to a coding region, wherein the coding region encodes a target gene and the riboswitch modulates translation or transcription of the coding region.

### Claim 2 (depends on 1)

The genetic construct of claim 1 wherein the target gene is a gene where background levels of expression, even at a low level, can cause harm to the cell.

### Claim 3 (depends on 1, 2)

The genetic construct of claim 1 or claim 2 wherein the riboswitch in the genetic construct may reduce the background level of target gene expression by about 5%, 10%, 20%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or more.

### Claim 4 (depends on 1, 2)

The genetic construct of claim 1 or claim 2 wherein the riboswitch in the genetic construct may eliminate detectable background expression.

### Claim 5

The genetic construct of any preceding claim wherein the dynamic range of expression between the riboswitch being off and the riboswitch being on, and gene expression being activated, is low.

### Claim 6 (depends on 5)

The genetic construct of claim 5 wherein the dynamic range is between about 10 and about 100 fold of the off level.

### Claim 7

The genetic construct of any preceding claim wherein the riboswitch is 5′ to the coding region.

### Claim 8

The genetic construct of any preceding claim wherein the riboswitch comprises an aptamer domain which is capable of specifically binding to an inducer, and an expression platform which undergoes a conformational change in response to the binding of the inducer to the aptamer domain that promotes translation of the coding region.

### Claim 9

The genetic construct of any preceding claim wherein the riboswitch is a naturally-occurring riboswitch or a synthetic riboswitch.

### Claim 10 (depends on 9)

The genetic construct of claim 9 wherein the riboswitch specifically binds the inducer theophylline.

### Claim 11 (depends on 10)

The genetic construct of claim 10 wherein the riboswitch is a positive regulatory theophylline-responsive riboswitch, and optionally has the nucleotide sequence of SEQ ID NO. 1, 2, 3, 4, 5, 6 or 7.

### Claim 12 (depends on 11)

The genetic construct of claim 11 wherein the riboswitch has the nucleotide sequence of SEQ ID NO. 2.

### Claim 13

The genetic construct of any preceding claim wherein the target gene is an endonuclease.

### Claim 14 (depends on 13)

The genetic construct of claim 13 wherein the endonuclease can be used in genome-editing, and optionally wherein the endonuclease is a Zinc Finger Nuclease (ZFN), Transcription Activator-like Effector Nuclease (TALEN), Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) nuclease, homing meganuclease or standard restriction endonuclease (RE).

### Claim 15 (depends on 14)

The genetic construct of claim 14 wherein the endonuclease is Cas9, Cas9 nickase, dCas, Cpf1, C2c1, C2c2, C2c3, a Cas9 derivative, or any endonuclease suitable for use with CRISPR gene editing, or a homolog or functional variant thereof.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The genetic construct of any of claims 1 to 12 wherein the target gene is a sigma factor.

### Claim 17 (depends on 16)

The genetic construct of claim 16 wherein the sigma factors is TcdR (from Clostridium difficile), BotR (from Clostridium botulinum), TetR (from Clostridium tetani) or UviA (from Clostridium perfringens).

### Claim 18

A vector comprising the genetic construct of any preceding claim.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

A host cell comprising the genetic construct of any of claims 1 to 17 or a vector according to claim 18.

### Claim 20 (depends on 19)

The host cell of claim 19 wherein the cell is bacterium.

### Claim 21 (depends on 20)

The host cell of claim 20 wherein the bacterium is of the genus Bacillus or Clostridium.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

A kit for regulating expression of a target gene, wherein the kit comprises the genetic construct of any of claims 1 to 17.

### Claim 23

A method of controlling expression of a target gene in a cell comprising:
i) transforming a host cell with a genetic construct, the construct comprising polynucleotide to be transcribed, wherein the polynucleotide comprise is a coding region encoding a target gene operably linked to a riboswitch;
ii) exposing the transformed cell to an inducer of the riboswitch thereby effecting expression of the target gene.

### Claim 24

A method of controlling expression of a target gene in a cell comprising:
i) providing a host cell which contained a genetic construct, the construct comprising polynucleotide to be transcribed, wherein the polynucleotide comprise is a coding region encoding a target gene operably linked to a riboswitch;
ii) exposing the transformed cell to an inducer of the riboswitch thereby effecting expression of the target gene.
